ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q1Scopus Q1SCImago #264Top JournalReview JournalHybrid

Drug Resistance Updates

Abbreviation (ISO):DRUG RESIST UPDATE
•
Identifier (ISSN):1368-7646(Print)/1532-2084(Online)
•
Publisher:Churchill Livingstone
Clarivate IF (2026)
22↑ +0.3
Journal Impact Factor
IF Trend↓
WoS Quartile
Q1
WoS SCIETop Tier
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Drug Resistance Updates

WoS Q1
715243211.6201811.7201911.0202018.5202122.8202224.3202315.8202421.7202522.02026
Annual Impact Factor Metric
Current (2026):22
Scopus SJR & RankScopus Q1
5.279
#264

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
148

148 papers with at least that number of citations each

WoS: SCIE / JCRTop Tier
Self-Citation Rate4.4%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
21articles/year
35.71% Gold OA•6.25% Original Research

Aims & Scope

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance. It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine. Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective. *Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research

Topics Covered (Recognized by AI)
Medicine83.1%Biology81%Genetics77.9%Chemistry63.7%Biochemistry62.1%Internal medicine55.7%Microbiology42.1%Cancer39.4%Gene36.5%Cancer research35.6%Pharmacology33%Drug resistance31.8%Immunology28.5%Cell biology25.2%Pathology23.8%Psychology22.5%Psychiatry20.8%Organic chemistry20.5%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q1
Rank3/356
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q1
Rank2/356
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF22
Articles / Year100
Total Citations141
2025
IF21.7
Articles / Year110
Total Citations1,344
2024
IF15.8
Articles / Year115
Total Citations3,721
2023
IF24.3
Articles / Year83
Total Citations5,176
2022
IF22.841
Articles / Year48
Total Citations3,447

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #264Scopus Q1SCImago Profile
Scopus Coverage:1998-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q1
5.279

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1
Citations / Doc (2 years)
21.95

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$4,427 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations4,287
3-Year Documents201
Citable Documents192

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate39.6%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Cancer ResearchQ1
Infectious DiseasesQ1
OncologyQ1
PharmacologyQ1
Pharmacology (medical)Q1
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 4.4%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
1区 (Zone 1)Medicine
Minor Category (Specific Field):
1区PHARMACOLOGY & PHARMACY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Drug Resistance Updates (abbr: DRUG RESIST UPDATE, ISSN: 1368-7646) is a peer-reviewed international scholarly journal in the field of Medicine, published by Churchill Livingstone in England since 1998. The periodical holds a Journal Impact Factor (JIF) of 22.0, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 5.279 (Q1), an H-index of 148.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 21 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $4,427 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Churchill Livingstone
Publication Language
English
Frequency
Bimonthly
Founding Year
1998
Indexing & Databases
SCIEScopusPubMed
Editorial Address
CHURCHILL LIVINGSTONE, JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH, SCOTLAND, MIDLOTHIAN, EH1 3AF

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 6e17e2e0-e90c-4294-bb5d-0ab3c75eacf7
Database Updated: 2026-10-16